Tambeur L, David T E, Unger M, Armstrong S, Ivanov J, Webb G
Division of Cardiovascular Surgery, Toronto General Hospital and University of Toronto, Toronto, Ontario, Canada.
Eur J Cardiothorac Surg. 2000 Apr;17(4):415-9. doi: 10.1016/s1010-7940(00)00379-1.
To evaluate the results of two operations, aortic valve-sparing and aortic root replacement, in patients with aortic root aneurysm and the Marfan syndrome.
A retrospective review of 78 consecutive patients with aortic root aneurysm and the Marfan syndrome according to the Gent criteria indicated that 42 patients with normal aortic cusps had an aortic valve-sparing operation, and 36 patients had aortic root replacement (mechanical valve in 25 patients and biological valve in 11). The mean age was similar in both groups, but patients who had aortic root replacement had larger aneurysms, higher grade aortic insufficiency, worse left ventricular function and more cardiac co-morbidity than patients who had aortic valve-sparing operations. The mean follow-up was 41+/-35 months for patients who had aortic valve-sparing, and 65+/-50 months for those who had aortic root replacement.
Kaplan-Meyer estimates of survival at 5 years was 100% for patients who had aortic valve-sparing, and 88+/-6% for those who had aortic root replacement (P=0.04). Five patients who had aortic root replacement required seven aortic root re-replacements: three for endocarditis and four for valve failure (biological valves). There have been no reoperations in patients who had aortic valve-sparing operations and annual Doppler echocardiography revealed mild or no aortic insufficiency in 39 patients and moderate aortic insufficiency in three.
These data suggest that aortic valve-sparing operations are safe in patients with the Marfan syndrome and may provide better clinical outcomes than aortic root replacement. Since the size of the aneurysm often determines the feasibility of a valve-sparing procedure, we now recommend surgery when the diameter of the aortic root reaches 50 mm in patients with the Marfan syndrome who have echocardiographically normal aortic valve cusps.
评估保留主动脉瓣手术和主动脉根部置换术治疗主动脉根部瘤合并马方综合征患者的效果。
根据根特标准对78例连续的主动脉根部瘤合并马方综合征患者进行回顾性分析,结果显示,42例主动脉瓣叶正常的患者接受了保留主动脉瓣手术,36例患者接受了主动脉根部置换术(25例植入机械瓣膜,11例植入生物瓣膜)。两组患者的平均年龄相似,但与接受保留主动脉瓣手术的患者相比,接受主动脉根部置换术的患者动脉瘤更大、主动脉瓣关闭不全分级更高、左心室功能更差且心脏合并症更多。接受保留主动脉瓣手术患者的平均随访时间为41±35个月,接受主动脉根部置换术患者的平均随访时间为65±50个月。
接受保留主动脉瓣手术患者的5年Kaplan-Meyer生存估计值为100%,接受主动脉根部置换术患者的为88±6%(P=0.04)。5例接受主动脉根部置换术的患者需要进行7次主动脉根部再次置换:3例因心内膜炎,4例因瓣膜功能衰竭(生物瓣膜)。接受保留主动脉瓣手术的患者未进行再次手术,每年的多普勒超声心动图显示,39例患者存在轻度或无主动脉瓣关闭不全,3例存在中度主动脉瓣关闭不全。
这些数据表明,保留主动脉瓣手术对于马方综合征患者是安全的,并且可能比主动脉根部置换术提供更好的临床结果。由于动脉瘤大小通常决定保留瓣膜手术的可行性,我们现在建议,对于超声心动图显示主动脉瓣叶正常的马方综合征患者,当主动脉根部直径达到50 mm时进行手术。